Strategic Targeting for Optimal Prevention of Cancer
ClinLogic LLC
Summary
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.
Description
Data collection will be limited to study subjects 65 years or older. The genes evaluated may be modified from time to time by the Sponsor as the body of knowledge expands and important additional pathways are identified. The list of appropriate genes that may be considered by the treating physician includes but are not necessarily limited to the following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, TP53 and XRCC2. These subjects must also meet medical necessity for hereditary cancer genomic testing;…
Eligibility
- Age range
- 65+ years
- Sex
- All
- Healthy volunteers
- Not specified
Inclusion Criteria: * Study subjects may be included in the Clinical Trial if they meet all of the following inclusion criteria: * individuals, ages 65 years or older; * must have met medical necessity for hereditary cancer genomic testing and allowed the physician to test based on medical necessity; * hereditary cancer diagnostic test was ordered by a physician related to individual subject care considerations. * study subject has or had cancer * study subject has at least one family member with cirrent or past cancer Exclusion Criteria: * Study subjects will be excluded from th…
Interventions
- Diagnostic TestGenetic Testing
Buccal swab
Location
- Sunbeam ClinicalProsper, Texas